Designation follows recent US Breakthrough Therapy Designations for Enhertu for HER2-positive metastatic gastric cancer and HER2-mutant metastatic non-small cell lung cancer

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 22 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 May 2020 06:06:07 UTC